{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:17:18Z","timestamp":1784859438107,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016308","name":"Bpifrance","doi-asserted-by":"publisher","award":["Bpifrance"],"award-info":[{"award-number":["Bpifrance"]}],"id":[{"id":"10.13039\/100016308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01349-w","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:05:28Z","timestamp":1764943528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dosimetry and preclinical evaluation of long-term radiotoxicity following treatment with 212Pb alpha-radioimmunotherapy targeting CD20"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-8937","authenticated-orcid":false,"given":"Isabelle","family":"Quelven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Mora-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Torgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Durand-Panteix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1053\/j.semnuclmed.2022.12.006","volume":"53","author":"F Cicone","year":"2023","unstructured":"Cicone F, Santo G, Bodet-Milin C, Cascini GL, Kraeber-Bod\u00e9r\u00e9 F, Stokke C, et al. Radioimmunotherapy of non-Hodgkin B-cell lymphoma: an update. Semin Nucl Med. 2023;53:413\u201325. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.12.006.","journal-title":"Semin Nucl Med"},{"key":"1349_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/cbr.2019.3340","volume":"35","author":"H Jadvar","year":"2020","unstructured":"Jadvar H. Targeted \u03b1-therapy in cancer management: synopsis of preclinical and clinical studies. Cancer Biother Radiopharm. 2020;35:475\u201384. https:\/\/doi.org\/10.1089\/cbr.2019.3340.","journal-title":"Cancer Biother Radiopharm"},{"key":"1349_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3389\/fonc.2013.00324","volume":"3","author":"J Elgqvist","year":"2014","unstructured":"Elgqvist J, Frost S, Pouget J-P, Albertsson P. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 2014;3:324. https:\/\/doi.org\/10.3389\/fonc.2013.00324.","journal-title":"Front Oncol"},{"key":"1349_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"Y-S Kim","year":"2012","unstructured":"Kim Y-S, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol. 2012;33:573\u201390. https:\/\/doi.org\/10.1007\/s13277-011-0286-y.","journal-title":"Tumor Biol"},{"key":"1349_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010049","author":"BJB Nelson","year":"2020","unstructured":"Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics13010049.","journal-title":"Pharmaceutics"},{"key":"1349_CR6","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1039\/c0dt01387k","volume":"40","author":"K Yong","year":"2011","unstructured":"Yong K, Brechbiel MW. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 2011;40:6068\u201376. https:\/\/doi.org\/10.1039\/c0dt01387k.","journal-title":"Dalton Trans"},{"key":"1349_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0969-8051(99)00086-4","volume":"27","author":"LL Chappell","year":"2000","unstructured":"Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93\u2013100.","journal-title":"Nucl Med Biol"},{"key":"1349_CR8","doi-asserted-by":"publisher","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","volume":"15","author":"AF Maaland","year":"2020","unstructured":"Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS One. 2020;15:e0230526. https:\/\/doi.org\/10.1371\/journal.pone.0230526.","journal-title":"PLoS One"},{"key":"1349_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2967\/jnumed.119.239491","volume":"61","author":"I Quelven","year":"2020","unstructured":"Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, et al. 212Pb \u03b1-radioimmunotherapy targeting CD38 in multiple myeloma: a preclinical study. J Nucl Med. 2020;61:1058\u201365. https:\/\/doi.org\/10.2967\/jnumed.119.239491.","journal-title":"J Nucl Med"},{"key":"1349_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41416-021-01585-6","volume":"125","author":"S Durand-Panteix","year":"2021","unstructured":"Durand-Panteix S, Monteil J, Sage M, Garot A, Clavel M, Saidi A, et al. Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. Br J Cancer. 2021;125:1657\u201365. https:\/\/doi.org\/10.1038\/s41416-021-01585-6.","journal-title":"Br J Cancer"},{"key":"1349_CR11","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","volume":"113","author":"D Dayd\u00e9","year":"2009","unstructured":"Dayd\u00e9 D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113:3765\u201372. https:\/\/doi.org\/10.1182\/blood-2008-08-175125.","journal-title":"Blood"},{"key":"1349_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nmeth.1455","volume":"7","author":"DJ Langford","year":"2010","unstructured":"Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010;7:447\u20139. https:\/\/doi.org\/10.1038\/nmeth.1455.","journal-title":"Nat Methods"},{"key":"1349_CR13","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.1002\/anie.201004243","volume":"49","author":"S Jeger","year":"2010","unstructured":"Jeger S, Zimmermann K, Blanc A, Gr\u00fcnberg J, Honer M, Hunziker P, et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl. 2010;49:9995\u20137. https:\/\/doi.org\/10.1002\/anie.201004243.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1349_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/bc400574z","volume":"25","author":"P Dennler","year":"2014","unstructured":"Dennler P, Chiotellis A, Fischer E, Br\u00e9geon D, Belmant C, Gauthier L, et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014;25:569\u201378. https:\/\/doi.org\/10.1021\/bc400574z.","journal-title":"Bioconjug Chem"},{"key":"1349_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med. 2009;50:477\u201384. https:\/\/doi.org\/10.2967\/jnumed.108.056036.","journal-title":"J Nucl Med"},{"key":"1349_CR16","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1080\/09553002.2022.2033341","volume":"98","author":"I Liatsou","year":"2022","unstructured":"Liatsou I, Yu J, Bastiaannet R, Li Z, Hobbs RF, Torgue J, et al. 212Pb-conjugated anti-rat HER2\/neu antibody against a neu-N derived murine mammary carcinoma cell line: cell kill and RBE in vitro. Int J Radiat Biol. 2022;98:1452\u201361. https:\/\/doi.org\/10.1080\/09553002.2022.2033341.","journal-title":"Int J Radiat Biol"},{"key":"1349_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","volume":"46","author":"JC Dos Santos","year":"2019","unstructured":"Dos Santos JC, Sch\u00e4fer M, Bauder-W\u00fcst U, Lehnert W, Leotta K, Morgenstern A, et al. Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46:1081\u201391. https:\/\/doi.org\/10.1007\/s00259-018-4220-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1349_CR18","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","volume":"76","author":"LA Dawson","year":"2010","unstructured":"Dawson LA, Kavanagh BD, Paulino AC, Das SK, Miften M, Li XA, et al. Radiation-associated kidney injury. Int J Radiat Oncol Biol Phys. 2010;76:S108\u2013115. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.089.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1349_CR19","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10\u201319. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.07.1754.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1349_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/108497802760363222","volume":"17","author":"JA O\u2019Donoghue","year":"2002","unstructured":"O\u2019Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435\u201343. https:\/\/doi.org\/10.1089\/108497802760363222.","journal-title":"Cancer Biother Radiopharm"},{"key":"1349_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13014-015-0371-2","volume":"10","author":"T Gupta","year":"2015","unstructured":"Gupta T, Hotwani C, Kannan S, Master Z, Rangarajan V, Murthy V, et al. Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose\u2013response relationship of parotid-sparing radiotherapy in head-neck cancers. Radiat Oncol. 2015;10:67. https:\/\/doi.org\/10.1186\/s13014-015-0371-2.","journal-title":"Radiat Oncol"},{"key":"1349_CR22","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927\u201332.","journal-title":"Blood"},{"key":"1349_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.beha.2006.05.002","volume":"19","author":"TE Witzig","year":"2006","unstructured":"Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol. 2006;19:655\u201368. https:\/\/doi.org\/10.1016\/j.beha.2006.05.002.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1349_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.semnuclmed.2019.09.002","volume":"50","author":"JG Jurcic","year":"2020","unstructured":"Jurcic JG. Targeted alpha-particle therapy for hematologic malignancies. Semin Nucl Med. 2020;50:152\u201361. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.09.002.","journal-title":"Semin Nucl Med"},{"key":"1349_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1089\/cbr.2019.3405","volume":"35","author":"W Wojdowska","year":"2020","unstructured":"Wojdowska W, Karczmarczyk U, Balog L, Sawicka A, P\u00f6st\u00e9nyi Z, Kov\u00e1cs-Ha\u00e1sz V, et al. Impact of DOTA-chelators on the antitumor activity of 177Lu-DOTA-rituximab preparations in lymphoma tumor-bearing mice. Cancer Biother Radiopharm. 2020;35:558\u201362. https:\/\/doi.org\/10.1089\/cbr.2019.3405.","journal-title":"Cancer Biother Radiopharm"},{"key":"1349_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00259-009-1197-7","volume":"37","author":"J Dahle","year":"2010","unstructured":"Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, et al. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab. Eur J Nucl Med Mol Imaging. 2010;37:93\u2013102. https:\/\/doi.org\/10.1007\/s00259-009-1197-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1349_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2967\/jnumed.119.229393","volume":"61","author":"SR Banerjee","year":"2020","unstructured":"Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical evaluation of 203\/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61:80\u20138. https:\/\/doi.org\/10.2967\/jnumed.119.229393.","journal-title":"J Nucl Med"},{"key":"1349_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","volume":"51","author":"E Vegt","year":"2010","unstructured":"Vegt E, de Jong M, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049\u201358. https:\/\/doi.org\/10.2967\/jnumed.110.075101.","journal-title":"J Nucl Med"},{"key":"1349_CR29","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","volume":"41","author":"C Kratochwil","year":"2014","unstructured":"Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106\u201319. https:\/\/doi.org\/10.1007\/s00259-014-2857-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1349_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2017.1322577","volume":"17","author":"M Bourgeois","year":"2017","unstructured":"Bourgeois M, Bailly C, Frindel M, Guerard F, Ch\u00e9rel M, Faivre-Chauvet A, et al. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opin Biol Ther. 2017;17:813\u20139. https:\/\/doi.org\/10.1080\/14712598.2017.1322577.","journal-title":"Expert Opin Biol Ther"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01349-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01349-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01349-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:07:50Z","timestamp":1768342070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-025-01349-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01349-w","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable international, national, and institutional guidelines for the care and use of animals were followed. The study protocol was approved by the Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur, de la Recherche et de l\u2019Innovation (APAFIS#15900-201807061621591 v2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Amal Saidi and Julien Torgue are employees of Orano Med and were involved in the dosimetry analyses and the interpretation of the manuscript data. No other potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}